Filing Flows › Maxcyte (MXCT) › Licenses revenue
Maxcyte (MXCT) Licenses revenue by quarter
Maxcyte's Licenses revenue was $2.6M in Q2 2026 (second quarter 2026), -53% from Q1 2026. Over the last 6 quarters it ranged from $2.2M (Q3 2025) to $5.5M (Q1 2026).
| Quarter | Licenses revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.6M | -53% | -12% |
| Q1 2026 | $5.5M | +118% | +18% |
| Q4 2025 | $2.5M | +14% | — |
| Q3 2025 | $2.2M | -24% | — |
| Q2 2025 | $2.9M | -37% | — |
| Q1 2025 | $4.7M | — | — |
Q2 2026 at a glance
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Maxcyte's Licenses revenue?
Maxcyte's Licenses revenue was $2.6M in Q2 2026 (second quarter 2026), -53% from Q1 2026.
How has Maxcyte's Licenses revenue changed?
Over the last 6 quarters it ranged from $2.2M (Q3 2025) to $5.5M (Q1 2026).